Small molecule control of neurotransmitter sulfonation.

The Journal of Biological Chemistry
Ian CookThomas S Leyh

Abstract

Controlling unmodified serotonin levels in brain synapses is a primary objective when treating major depressive disorder - a disease that afflicts ~20% of the world's population. Roughly 60% of patients respond poorly to first-line treatments and thus new therapeutic strategies are sought. Toward this end, we have constructed isoform-specific inhibitors of the human cytosolic sulfotransferase 1A3 (SULT1A3) - the isoform responsible for sulfonating ~80% of the serotonin in extracellular brain fluid. The inhibitor design includes a core ring structure, which anchors the inhibitor into a SULT1A3-specific binding pocket located outside the active site, and a sidechain crafted to act as a latch to inhibit turnover by fastening down the SULT1A3 active-site cap. The inhibitors are allosteric, they bind with nanomolar affinity and are highly specific for the 1A3 isoform. The cap-stabilizing effects of the latch can be accurately calculated and are predicted to extend throughout the cap and into the surrounding protein. A free energy correlation demonstrates that the percent inhibition at saturating inhibitor varies linearly with cap stabilization - the correlation is linear because the rate-limiting step of the catalytic cycle, nucleot...Continue Reading

References

Jul 1, 1983·British Journal of Clinical Pharmacology·M J Stewart, I D Watson
Mar 19, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·D SoueryJ Mendlewicz
Aug 12, 2003·Proteins·Marcel L VerdonkRichard D Taylor
Aug 9, 2005·Biochemical and Biophysical Research Communications·Jing-Hua LuWen-Rui Chang
Nov 23, 2005·Bioinformatics·Konstantin ArnoldTorsten Schwede
Dec 31, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Josie L FalanyCharles N Falany
Jan 24, 2006·Nature Reviews. Neuroscience·Olivier Berton, Eric J Nestler
Mar 22, 2006·Oncogene·S Nowell, C N Falany
Nov 30, 2006·PLoS Medicine·Colin D Mathers, Dejan Loncar
Jul 11, 2008·Journal of Computational Chemistry·Jon BakerPeter Pulay
Jan 28, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Emily D SalmanCharles N Falany
Aug 15, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Zoe RichesMichael W H Coughtrie
May 1, 2010·Biochemistry·Meihao Sun, Thomas S Leyh
Sep 22, 2010·Journal of the American Academy of Child and Adolescent Psychiatry·Kathleen Ries MerikangasJoel Swendsen
Mar 9, 1994·Journal of the American Chemical Society·Eric S Eberhardt, Ronald T Raines
Apr 3, 2012·Journal of Chemical Information and Modeling·Alessandra NurissoAntoine Daina
Jun 19, 2012·Biochemistry·Ian CookThomas S Leyh
Dec 22, 2012·Biochemistry·Ian CookThomas S Leyh
Jan 31, 2013·The Journal of Biological Chemistry·Ian CookThomas S Leyh
Jun 4, 2014·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Edward ChesneySeena Fazel
Jul 25, 2014·The Journal of Biological Chemistry·Ting WangThomas S Leyh
Dec 24, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ian CookThomas S Leyh
Sep 5, 2015·Biochemistry·Ian CookThomas S Leyh
May 21, 2016·Cell Chemical Biology·Ian CookThomas S Leyh
Jun 30, 2016·Biochemistry·Ting WangThomas S Leyh
Oct 19, 2017·The Journal of Biological Chemistry·Ting WangThomas S Leyh
Jun 25, 2018·Archives of Biochemistry and Biophysics·Gregory A Grant
Nov 14, 2018·Biochemical Pharmacology·Ian CookThomas S Leyh
Dec 14, 2018·The Journal of Biological Chemistry·Kristie DarrahThomas S Leyh

❮ Previous
Next ❯

Software Mentioned

MODEL
Antechamber
SWISS
AMBER
GROMACS
AmberTools
Parallel Quantum Solutions

Related Concepts

Related Feeds

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.